Oncolys BioPharma Inc. (TYO:4588)
Japan · Delayed Price · Currency is JPY 2,858.00
+101.00 (3.66%)
May 12, 2026, 3:30 PM JST
Oncolys BioPharma Cash Flow Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | -1,685 | -1,939 | -1,149 | -1,615 | -2,095 |
Depreciation & Amortization | 0.82 | 2.29 | 0.91 | 6.49 | 4.89 |
Other Amortization | - | 8.78 | - | - | - |
Loss (Gain) From Sale of Assets | - | - | - | 90.98 | - |
Asset Writedown & Restructuring Costs | 17.1 | 21.9 | 4.4 | 19.85 | 11.14 |
Loss (Gain) From Sale of Investments | - | - | -21.41 | - | 321 |
Stock-Based Compensation | 25.63 | 10.06 | 75.93 | 277.48 | 390.51 |
Provision & Write-off of Bad Debts | - | - | - | - | 35.68 |
Other Operating Activities | -9.85 | 6.15 | -71.31 | -41.75 | 16.91 |
Change in Accounts Receivable | - | - | 352.15 | -281.55 | 98.71 |
Change in Inventory | 0.76 | 18.91 | -12.59 | -1.18 | 4.44 |
Change in Accounts Payable | -141.35 | 132.73 | -45.37 | -100.34 | -60.9 |
Change in Unearned Revenue | - | - | -285.76 | - | - |
Change in Other Net Operating Assets | -228.42 | 400.78 | -565.15 | -96.36 | -192.5 |
Operating Cash Flow | -2,020 | -1,337 | -1,717 | -1,742 | -1,465 |
Capital Expenditures | -3.52 | -5.69 | -1.36 | -1.44 | -2.7 |
Sale of Property, Plant & Equipment | - | 0.14 | - | - | - |
Cash Acquisitions | - | - | - | - | -10.76 |
Investment in Securities | -0 | -0 | 21.41 | 0.49 | -0.01 |
Other Investing Activities | -1.19 | 0.16 | 0.07 | 0.01 | -2.35 |
Investing Cash Flow | -4.71 | -5.39 | 20.12 | -0.94 | -37.58 |
Long-Term Debt Issued | 100 | 100 | 100 | 100 | 100 |
Short-Term Debt Repaid | - | - | -100 | - | - |
Long-Term Debt Repaid | -106.37 | -198.98 | -113.77 | -124.84 | -103.15 |
Total Debt Repaid | -106.37 | -198.98 | -213.77 | -124.84 | -103.15 |
Net Debt Issued (Repaid) | -6.37 | -98.98 | -113.77 | -24.84 | -3.15 |
Issuance of Common Stock | 2,891 | 1,242 | - | 3,128 | 245.51 |
Repurchase of Common Stock | -5 | - | -0.03 | -0.04 | -0.1 |
Other Financing Activities | -0 | - | -0.03 | -12.07 | -0 |
Financing Cash Flow | 2,879 | 1,143 | -113.83 | 3,091 | 242.26 |
Foreign Exchange Rate Adjustments | 23.5 | 21.33 | 67.41 | 38.17 | -14.15 |
Miscellaneous Cash Flow Adjustments | - | - | 0 | -0 | -0 |
Net Cash Flow | 878.16 | -178.44 | -1,743 | 1,387 | -1,275 |
Free Cash Flow | -2,024 | -1,343 | -1,718 | -1,743 | -1,468 |
Free Cash Flow Margin | -6447.89% | -2129.84% | -176.04% | -271.33% | -467.22% |
Free Cash Flow Per Share | -92.69 | -75.44 | -99.18 | -103.06 | -102.00 |
Cash Interest Paid | 4.34 | 3.84 | 3.96 | 4.19 | 4.32 |
Cash Income Tax Paid | 2.94 | -25.37 | 1.47 | 3.73 | 3.73 |
Levered Free Cash Flow | -1,428 | -566.1 | -943.47 | -1,012 | -788.94 |
Unlevered Free Cash Flow | -1,425 | -563.85 | -941.01 | -1,009 | -786.34 |
Change in Working Capital | -369.01 | 552.41 | -556.72 | -479.43 | -150.24 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.